KLDO (Kaleido Biosciences) Total Receivables: $0.00 Mil (As of Dec. 2021)


What is Kaleido Biosciences Total Receivables?

Kaleido Biosciences KLDO -99.00% Total Receivables is $0.00 Mil as of Dec. 2021.

Kaleido Biosciences's Total Receivables for the quarter that ended in Dec. 2021 was $0.00 Mil.

Kaleido Biosciences Total Receivables Related Terms

Kaleido Biosciences Total Receivables Historical Data

* Premium members only.

The historical data trend for Kaleido Biosciences's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kaleido Biosciences Total Receivables Chart

Kaleido Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Total Receivables
Get a 7-Day Free Trial 0.05 0.00 0.00 0.00 0.00

Kaleido Biosciences Quarterly Data
Dec16 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Kaleido Biosciences Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.00 Mil mean?
Kaleido Biosciences (KLDO) has a Total Receivables of $0.00 Mil as of Dec. 2021. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Kaleido Biosciences and its competitors.
Is Kaleido Biosciences' Total Receivables too high?
Kaleido Biosciences' current Total Receivables is $0.00 Mil.
How does Kaleido Biosciences' Total Receivables compare to NPTX and GSTC?
Kaleido Biosciences' Total Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Kaleido Biosciences and its competitors. Kaleido Biosciences's current Total Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaleido Biosciences stock overvalued right now?
Kaleido Biosciences (KLDO) has a current Total Receivables of $0.00 Mil. The current Total Receivables is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Kaleido Biosciences (KLDO), the current Total Receivables is $0.00 Mil as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kaleido Biosciences Business Description

Address 65 Hayden Avenue, Lexington, MA, USA, 02421
Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome.